Michael Paxten, MD
Hand Surgery · Rome, GANPI 1023246923
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $620 of the $907 with a category attached, or 68.3%. 16 manufacturers reported payments, led by Arthrex at 43.8% of the total. Reporting peaked in 2019 at $540 and has fallen 67.8% since, to $174 in 2025. That places this record below the midpoint for hand surgery clinicians in GA, where the typical reported total is $1,780.
Across 28 payments — averaging $32.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$398
- Axogen$194
- Johnson & Johnson$82
- Amgen$44
- Sonex Health, Inc.$24
- Zimmer Biomet$22
- plus $143 from 10 others
What the payments were for
- Travel & lodging$28732%
- Food & beverage$62068%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 10 | $398 |
| Axogen | 2 | $194 |
| Johnson & Johnson | 1 | $82 |
| Amgen(2 entities) | 3 | $44 |
| Sonex Health, Inc. | 1 | $24 |
| Zimmer Biomet | 1 | $22 |
| Endo Pharmaceuticals Inc. | 1 | $20 |
| Pacira Therapeutics, Inc. | 1 | $17 |
| Organogenesis Inc. | 1 | $15 |
| Pacira Pharmaceuticals Incorporated | 1 | $15 |
| Si-bone, Inc. | 1 | $15 |
| Anika Therapeutics, Inc. | 1 | $14 |
| Integra Lifesciences Corporation | 1 | $14 |
| Trice Medical, Inc. | 1 | $12 |
| Dynasplint Systems Inc. | 1 | $11 |
| Arthrosurface Incorporated | 1 | $11 |
How this compares
$907 in reported general payments places this provider in the 25th percentile of 77 hand surgery providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 111 | $758 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 63 | $378 |
| Celecoxib | 17 | $229 |
| Meloxicam | 101 | $184 |
| Ibuprofen | 16 | $145 |
| Cephalexin | 15 | $80 |
| Gabapentin | 14 | $58 |
| Tramadol Hcl | 15 | $38 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 17 | $20 |
Paid to pharmacies, not to this prescriber.
Other hand surgery in Rome
- Jarrad BarberRome$15K
- Eric WagnerAtlanta$173K
- Phani DantuluriAtlanta$120K
- Gregory KolovichSavannah$103K
- Michael ShulerAthens$99K
- Travis LittletonAtlanta$35K
- Nicole ZelenskiAtlanta$34K
- Justin BarrettGainesville$33K
- Tobias von BergenStockbridge$27K
- James SprattAtlanta$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.